quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:20:00·7d
PRRelease
MAIA Biotechnology Inc. logo

MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer

MAIA· MAIA Biotechnology Inc.
Health Care
Original source

Companies

  • MAIA
    MAIA Biotechnology Inc.
    Health Care

Related

  • SEC7d
    MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits
  • INSIDER9d
    SEC Form 4 filed by Vitoc Vlad
  • INSIDER9d
    SEC Form 4 filed by Gryaznov Sergei
  • INSIDER9d
    SEC Form 4 filed by Himmelreich Jeffrey C
  • SEC15d
    MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits
  • PR15d
    MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
  • SEC16d
    SEC Form S-8 filed by MAIA Biotechnology Inc.
  • SEC16d
    SEC Form DEFA14A filed by MAIA Biotechnology Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022